Videos

Dr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for bispecific therapy, including local health care barriers, and strategies for ensuring consistent patient education and support when care is shared between community and academic centers.

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.

Experts discuss the most common adverse events associated with the FOLFOX regimen and effective strategies for early detection and management.

Experts discuss Robert’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment approaches and challenges.

Key opinion leaders focus on educating patients about potential side effects of lorlatinib and other ALK inhibitors, including guidance on when to contact their care team.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN

Medical experts discuss strategies for managing adverse events associated with KRAS-targeted therapies, addressing monitoring challenges with oral medications and balancing symptom management with treatment efficacy.

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, RN.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific therapy, as well as best practices for transitioning care back to the community center after therapy administration.

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for effectively initiating these discussions with patients.

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Key opinion leaders compare osimertinib's adverse event profile to other EGFR inhibitors, highlighting specific challenges and benefits observed in clinical practice

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

Key opinion leaders highlight effective multidisciplinary strategies for managing the diverse range of side effects associated with EGFR inhibitors.

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE profiles of talquetamab, teclistamab, and elranatamab, highlighting unique challenges and benefits.

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on preventive measures and comparisons with GI management strategies for other EGFR inhibitors.

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, discussing unique challenges and benefits observed in clinical practice.

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, highlighting multidisciplinary management strategies and integrating best practices into electronic medical records.

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including preventive measures and comparisons to managing GI issues from other EGFR inhibitors.

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle support, balancing work during and after treatment, and effective supportive care measures.

This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting monitoring strategies, tools for early detection, and approaches to communicating risks with patients and caregivers.